Key result
Ivabradine shows potential to improve endothelial function, arterial stiffness, and inflammation beyond heart failure.
Why the study?
Emerging effects of ivabradine on endothelial and myocardial function, oxidative stress, and inflammation prompted a review of newer evidence and potential applications beyond guideline-based clinical practice.
Answers are grounded in this paper and cite their sources.
Emerging evidence suggests ivabradine may offer vascular and myocardial protective effects beyond its established guideline-directed indications for heart rate reduction.
Ivabradine is a pure heart-rate lowering drug that is nowadays used, accordingly to the last ESC Guidelines, to reduce mortality and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction and in symptomatic patiens with inappropriate sinus tachycardia. Moreover, interesting effect of ivabradine on endothelial and myocardial function and on oxidative stress and inflamation pathways are progressively emerging. The aim of this paper is to highlight newer evidences about ivabradine effect (and consequently possible future application of the drug) in pathological settings different from guidelines-based clinical practice.
No takes yet. Share an insight, caveat, or question.
Dallapellegrina et al. (2020) conducted a review in Heart failure, inappropriate sinus tachycardia, and cardiovascular disease. Ivabradine was evaluated. Ivabradine demonstrates emerging potential to improve oxidative and inflammatory status, endothelial function, arterial stiffness, and diastolic function beyond its established role in heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: